<DOC>
	<DOC>NCT01091311</DOC>
	<brief_summary>Multicentric study, open label, uncontrolled phase IV in 30 patients with meibomian glands dysfunction . Its objective is to Collect information from patients and ophthalmologists specialized in ocular surface and eyelids to anticipate how Blephasteam ® can be optimized. This study involves 2 visits, visit of Inclusion, J0, then end of study visit, D21. Between the two visits patients will be treated with Blephasteam ® for 21 days (up to two uses per day) and complete a questionnaire every two days during the first week and then once a week the next two weeks.</brief_summary>
	<brief_title>Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases</brief_title>
	<detailed_description />
	<mesh_term>Eyelid Diseases</mesh_term>
	<criteria>Signed and dated informed consent. Male or female up to 4 years old. Known and treated symptomatic Meibomian Gland Diseases, and/or Dry Eye related to MGDs stable since at least a month. Without any active pathology requiring a change in ocular treatments within the last month before inclusion. Best corrected far visual acuity (VA) &gt; 1/10</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Meibomian Gland Dysfunction</keyword>
</DOC>